Should the government get a cut of the profits from pricey drugs birthed as research projects inside government-funded labs? That question has been sparking a debate, thanks in large part to newly elected U.S. Rep. Alexandria Ocasio-Cortez (D-N.Y.).

At a congressional hearing this week in Washington, Ocasio-Cortez expressed the view that the National Institutes of Health act like an early investor in the development of drugs. But when those drugs later become privatized, the government receives no return on its investment. Her view prompted pushback from some in the drug industry, including Derek Lowe. A medicinal chemist for 30 years, he currently works on drug discovery projects for a large pharmaceutical company in the Boston area.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy